ReviewCell communication and signaling : CCS2025
The heterogeneity of monocyte-derived macrophages in MASH pathogenesis.
Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Autophagy in MASLD: A Metabolic and Precision Medicine Perspective.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Review
- Review
- Targeting STE20-type kinase MST3 improves metabolic dysfunction-associated steatohepatitis without affecting hepatocellular carcinoma development in mice.BMC medicine · 2026Article
- Revisiting macrophage metabolic reprogramming in metabolic dysfunction-associated steatotic liver disease: mechanisms, regulation, and therapeutic breakthroughs.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the leading global cause of chronic liver disease. Its more severe inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), often progresses to cirrhosis and hepatocellular carcinoma. However, the pathogenic mechanisms underlying MASH remain insufficiently defined. Hepatic macrophages, particularly monocyte-derived macrophages (MDMs), have recently been identified as key mediators in disease progression. This review summarizes the current evidence on the heterogeneity of MDMs in MASH pathogenesis, focusing on distinct subsets and their roles in either promoting or resolving hepatic inflammation. Additionally, the review provides an in-depth exploration of the mechanisms driving MDM differentiation, which contribute to their functional diversity. A more comprehensive understanding of MASH pathogenesis is essential for the identification of novel and effective therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.